
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases
Arrowhead Highlights Clinical-Stage RNAi Therapies for Obesity and Metabolic Diseases Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) recently showcased promising preclinical data supporting the advancement of two first-in-class, RNA interference (RNAi)-based investigational therapeutics, ARO-INHBE and ARO-ALK7, for the treatment of obesity and…